Radiochemotherapy With Cetuximab, Cisplatin, and Amifostine for Locally Advanced Head and Neck Cancer: A Feasibility Study

International Journal of Radiation Oncology Biology Physics

Volumn 77, Issue 1, 2010, Pages 9-15

  Koukourakis, Michael I ^a   Tsoutsou, Pelagia G ^a   Karpouzis, Antonios ^a   Tsiarkatsi, Maria ^a   Karapantzos, Ilias ^a   Daniilidis, Vassilios ^a   Kouskoukis, Constantinos ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Acceleration; Amifostine; Cetuximab; Cisplatin; Radiotherapy

Indexed keywords

AMIFOSTINE; CETUXIMAB; CIS-PLATIN; COMPLETE RESPONSE; CYTOPROTECTION; FEASIBILITY STUDIES; FUNGAL INFECTION; HEAD-AND-NECK CANCER; HEAD/NECK; HIGH INCIDENCE; LOCAL CONTROL; MUCOSITIS; NASOPHARYNGEAL CANCER; RADIOCHEMOTHERAPY; SALIVARY FUNCTION; SURVIVAL RATE;

COST REDUCTION; DECISION MAKING; PLANNING; PLATINUM COMPOUNDS; RESOURCE ALLOCATION; STANDARDS;

RADIOTHERAPY;

AMIFOSTINE; CETUXIMAB; CISPLATIN; CLINDAMYCIN; DOXYCYCLINE; NYSTATIN; POSACONAZOLE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL PROTECTION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SAFETY; FATIGUE; FEASIBILITY STUDY; FEMALE; FEVER; FOLLOW UP; HEAD AND NECK CANCER; HEMOGLOBIN BLOOD LEVEL; HUMAN; LARYNX EDEMA; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYCOSIS; NASOPHARYNX CANCER; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; RADIATION DERMATITIS; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RASH; SIDE EFFECT; SKIN EXFOLIATION; THERAPY DELAY; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; AMIFOSTINE; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MUCOSITIS; MYCOSES; PROSPECTIVE STUDIES; RADIODERMATITIS; XEROSTOMIA;

EID: 77950551290     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.04.060     Document Type: Article

References (23)

1. Forastiere AA, Ang KK, Brizel DNY. Head and neck cancers. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology, version 2.2008. http://www.nccn.org.
2. Ang K.K. Multidisciplinary management of locally advanced SCCHN: Optimizing treatment outcomes. Oncologist 13 (2008) 899-910
3. Pignon J.P., Bourhis J., Domenge C., et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. Lancet 355 (2000) 949-955
4. Bourhis J., Amand C., Pignon J.-P., et al. Update of MACH-NC (meta-analysis of chemotherapy in head and neck cancer) database focused on concomitant chemoradiotherapy. J Clin Oncol 22 Suppl (2004) 5505
5. Bourhis J., Overgaard J., Audry H., et al. for the Meta-Analysis of Radiotherapy in Carcinomas of Head and Neck (MARCH) Collaborative Group. Hyperfractionated or accelerated radiotherapy in head and neck cancer: A meta-analysis. Lancet 368 (2006) 843-854
6. Overgaard J., Hansen H.S., Specht L., et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 362 (2003) 933-940
7. Fu K.K., Pajak T.F., Trotti A., et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003. Int J Radiat Oncol Biol Phys 48 (2000) 7-16
8. Bourhis J., Lapeyre M., Tortochaux J., et al. Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer: A GORTEC trial. J Clin Oncol 24 (2006) 2873-2878
9. Horiot J.C., Le Fur R., N'Guyen T., et al. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: Final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol 25 (1992) 231-241
10. Brizel D.M., Albers M.E., Fisher S.R., et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 338 (1998) 1798-1804
11. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 (2006) 567-578
12. Vermorken J.B., Mesia R., Rivera F., et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359 (2008) 1116-1127
13. Brizel D.M., Wasserman T.H., Henke M., et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 18 (2000) 3339-3345
14. Koukourakis M.I., Giatromanolaki A., Danielidis V., and Sivridis E. Hypoxia inducible factor (HIF1alpha and HIF2alpha) and carbonic anhydrase 9 (CA9) expression and response of head-neck cancer to hypofractionated and accelerated radiotherapy. Int J Radiat Biol 84 (2008) 47-52
15. Maciejewski B., and Majewski S. Dose fractionation and tumour repopulation in radiotherapy for bladder cancer. Radiother Oncol 21 (1991) 163-170
16. Koukourakis M., Hlouverakis G., Kosma L., et al. The impact of overall treatment time on the results of radiotherapy for nonsmall cell lung carcinoma. Int J Radiat Oncol Biol Phys 34 (1996) 315-322
17. Koukourakis M.I., Abatzoglou I., Sivridis L., Tsarkatsi M., and Delidou H. Individualization of the subcutaneous amifostine dose during hypofractionated/accelerated radiotherapy. Anticancer Res 26 (2006) 2437-2443
18. Boccia R., Anné P.R., Bourhis J., Brizel D., Daly C., Holloway III N., Hymes S., Koukourakis M., Kozloff M., Turner M., and Wasserman T. Assessment and management of cutaneous reactions with amifostine administration: Findings of the ethyol (amifostine) cutaneous treatment advisory panel (ECTAP). Int J Radiat Oncol Biol Phys 60 (2004) 302-309
19. Eriksen J.G., and Steiniche T. Overgaard J for the Danish Head and Neck Cancer study group (DAHANCA). The role of epidermal growth factor receptor and E-cadherin for the outcome of reduction in the overall treatment time of radiotherapy of supraglottic larynx squamous cell carcinoma. Acta Oncol 44 (2005) 50-58
20. Koukourakis M.I., Bentzen S.M., Giatromanolaki A., et al. Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J Clin Oncol 24 (2006) 727-735
21. Giro C., Berger B., Bölke E., Ciernik I.F., et al. High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: Results of a survey in EORTC institutes. Radiother Oncol 90 (2009) 166-171
22. Pryor D.I., Porceddu S.V., Burmeister B.H., et al. Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer. Radiother Oncol 90 (2009) 166-171
23. Pfister D.G., Su Y.B., Kraus D.H., et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: A pilot phase II study of a new combined-modality paradigm. J Clin Oncol 24 (2006) 1072-1078